CV2 Antibody, IgG by CBA-IFA With Reflex to Titer, CSF
Also known as: CV2 CSF
Use
CV2 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.
Special Instructions
If CV2 Antibody IgG Screen by IFA, CSF is positive, then CV2 Antibody IgG Titer, CSF will be added. Additional charges apply. Serum is the preferred specimen.
Limitations
This assay utilizes CV2 transfected cell lines for the detection and semiquantification of the CV2 IgG antibody. A negative result does not rule out a diagnosis of autoimmune neurologic disease, and must be interpreted in conjunction with other clinical and laboratory data.
New York Approved
Methodology
Immunoassay (Indirect Fluorescent Antibody)
Biomarkers
LOINC Codes
- 53707-6
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
0.5 mL
Minimum Volume
0.15 mL
Container
ARUP standard transport tube
Storage Instructions
Refrigerated storage recommended
Causes for Rejection
Hemolyzed, contaminated, or severely lipemic specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |